マルチがん早期発見の世界市場レポート 2025年

マルチがん早期発見市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR19.1％で34億9,000万米ドルに成長します。予測期間の成長は、遠隔医療とデジタルヘルスの拡大、予防ヘルスケアの重視の高まり、プレシジョン・オンコロジーの採用拡大、バイオマーカー探索の進歩、消費者直接遺伝子検査の急増などに起因すると考えられます。予測期間における主な動向には、AIと機械学習の利用拡大、リキッドバイオプシー技術の採用拡大、マルチオミクスアプローチの統合、在宅検査キットの拡大、早期がん検出への注目の高まり、低侵襲診断法の開発などがあります。

個別化医療の採用拡大が、将来の多発がん早期発見市場の拡大を後押しします。個別化医療は、個人の特性や遺伝的構成に基づいてヘルスケア介入をカスタマイズするもので、治療効果を高めることができることから支持を集めています。この動向に拍車をかけているのは、ゲノミクスの進歩、疾病の複雑化、支持的な規制の枠組みです。個別化医療は、スクリーニングや治療アプローチを個人の遺伝子やバイオマーカーのプロファイルに合わせて調整することで、複数のがんの早期発見の有効性を増幅します。例えば、2024年2月にFDAが承認した希少疾患の新規個別化治療薬は、2022年の6種類から16種類に増加しました。従って、個別化医療の受け入れが増加していることが、多がん早期発見市場の成長を促進しています。

多発がん早期発見市場の主要企業は、ctDNAベースのリキッドバイオプシー検査を革新して感度、特異度、早期発見率を向上させ、最終的に患者の転帰を向上させています。これらの検査は血流中の循環腫瘍DNAを検出し、腫瘍の動態、治療反応、早期再発や微小残存病変を追跡する非侵襲的な方法を提供します。例えば、2023年5月、米国のがん診断会社ルーセンスは、先駆的なマルチがん早期発見（MCED）血液検査であるLucenceINSIGHTを米国本社で発表しました。このctDNAベースのリキッドバイオプシー検査は、1回の血液サンプルで10種類の一般的ながんのスクリーニングを可能にします。世界のがん死亡の約78%は、日常的なスクリーニング・プロトコルがないタイプに関連しており、この血液検査は、様々ながんタイプのスクリーニングを求める無症状の人々にとって、利便性とアクセス性の向上を提供します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界マルチがん早期発見PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のマルチがん早期発見市場：成長率分析
• 世界のマルチがん早期発見市場の実績：規模と成長, 2019-2024
• 世界のマルチがん早期発見市場の予測：規模と成長, 2024-2029, 2034F
• 世界マルチがん早期発見総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のマルチがん早期発見市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 液体生検
• 遺伝子パネル
• 臨床検査（LDT）
• その他のタイプ
• 世界のマルチがん早期発見市場がんの種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 固形腫瘍
• 造血悪性腫瘍
• 世界のマルチがん早期発見市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 診断検査室
• その他のエンドユーザー
• 世界のマルチがん早期発見市場、液体生検の種類のサブセグメンテーション、種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 循環腫瘍細胞（CTC）
• 循環腫瘍DNA（Ctdna）
• エクソソーム
• 世界のマルチがん早期発見市場、遺伝子パネルのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• DNAベースのパネル
• RNAベースのパネル
• マルチ遺伝子パネル
• 世界のマルチがん早期発見市場、臨床検査（LDT）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• PCR検査
• 次世代シーケンシング（NGS）検査
• 免疫組織化学（IHC）検査
• 世界のマルチがん早期発見市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• タンパク質バイオマーカー
• 自己抗体に基づく検査

第7章 地域別・国別分析

• 世界のマルチがん早期発見市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のマルチがん早期発見市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• マルチがん早期発見市場：競合情勢
• マルチがん早期発見市場：企業プロファイル
  • Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sysmex Inostics GmbH Overview, Products and Services, Strategy and Financial Analysis
  • Exact Sciences Corporation Overview, Products and Services, Strategy and Financial Analysis
  • Natera Inc Overview, Products and Services, Strategy and Financial Analysis
  • Guardant Health Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Core Diagnostics
• Genecast Biotechnology Co. Ltd
• Burning Rock Biotech Limited
• Freenome Holdings Inc.
• Guangzhou AnchorDx Medical Co. Ltd
• Singlera Genomics Incorporated
• Naveris Inc.
• Lucence Health Inc.
• PredOmix Technologies
• Micronoma INC.
• EarlyDiagnostics（EarlyDx）
• Elypta AB
• Predictive Oncology
• ANPAC Bio-Medical Science Co. Ltd
• CanSense Ltd

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• マルチがん早期発見市場2029：新たな機会を提供する国
• マルチがん早期発見市場2029：新たな機会を提供するセグメント
• マルチがん早期発見市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Multi-cancer early detection involves identifying and diagnosing various cancer types in their early stages through the examination of biomarkers and other indicators present in bodily fluids or tissues. The objective is to detect cancerous conditions affecting multiple organs or tissues before symptoms appear, thereby facilitating prompt intervention and enhancing treatment effectiveness.

The primary categories of multi-cancer early detection include liquid biopsy, gene panels, laboratory-developed tests (LDT), and other methodologies. Liquid biopsy, for instance, is a non-invasive diagnostic procedure that identifies cancer-related biomarkers, such as circulating tumor cells (CTCs) or cell-free DNA (cfDNA), from bodily fluids such as blood or urine. These tests provide valuable information on cancer detection, progression, and response to treatment. They are utilized across hospitals, diagnostic facilities, and other medical settings for diagnosing various cancer types, including both solid tumors and hematological malignancies.

The multi cancer early detection market research report is one of a series of new reports from The Business Research Company that provides multi cancer early detection market statistics, including the multi cancer early detection industry global market size, regional shares, competitors with multi cancer early detection market share, detailed multi cancer early detection market segments, market trends, and opportunities, and any further data you may need to thrive in the multi cancer early detection industry. This multi cancer early detection market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The multi cancer early detection market size has grown rapidly in recent years. It will grow from $1.45 billion in 2024 to $1.74 billion in 2025 at a compound annual growth rate (CAGR) of 19.3%. The growth in the historic period can be attributed to increasing prevalence of cancer, government initiatives and funding, growing awareness about early cancer detection, expansion of healthcare infrastructure, rising adoption of personalized medicine, decreasing costs of genetic testing.

The multi cancer early detection market size is expected to see rapid growth in the next few years. It will grow to $3.49 billion in 2029 at a compound annual growth rate (CAGR) of 19.1%. The growth in the forecast period can be attributed to expansion of telemedicine and digital health, growing emphasis on preventive healthcare, increasing adoption of precision oncology, advances in biomarker discovery, surge in direct-to-consumer genetic testing. Major trends in the forecast period include increasing use of AI and machine learning, growing adoption of liquid biopsy techniques, integration of multi-omics approaches, expansion of at-home testing kits, rising focus on early-stage cancer detection, development of minimally invasive diagnostics.

The increasing adoption of personalized medicine is poised to drive the expansion of the multi-cancer early detection market in the future. Personalized medicine, which customizes healthcare interventions based on individual characteristics and genetic makeup, is gaining traction due to its ability to enhance treatment efficacy. This trend is fueled by advancements in genomics, the growing complexity of diseases, and supportive regulatory frameworks. Personalized medicine amplifies the effectiveness of multi-cancer early detection by tailoring screening and treatment approaches to individual genetic and biomarker profiles. For instance, in February 2024, the FDA approved 16 novel personalized therapies for rare diseases, up from six in 2022, including seven cancer treatments and three for various other conditions, as reported by the Personalized Medicine Coalition. Hence, the increasing embrace of personalized medicine is fostering growth in the multi-cancer early detection market.

Major companies in the multi-cancer early detection market are innovating ctDNA-based liquid biopsy tests to improve sensitivity, specificity, and early detection rates, ultimately enhancing patient outcomes. These tests detect circulating tumor DNA in the bloodstream, offering a non-invasive method to track tumor dynamics, treatment response, and early recurrence or minimal residual disease. For example, in May 2023, Lucence, a US-based cancer diagnostics firm, unveiled LucenceINSIGHT, a pioneering multi-cancer early detection (MCED) blood test, at their US headquarters. This ctDNA-based liquid biopsy test enables screening for 10 common cancers using a single blood sample. With approximately 78% of global cancer deaths linked to types lacking routine screening protocols, this blood test offers improved convenience and accessibility for asymptomatic individuals seeking screening for various cancer types.

In May 2023, Freenome Holdings Inc., a US-based biotechnology company, acquired Oncimmune Ltd. for an undisclosed sum. This acquisition is aimed at enhancing Freenome's early cancer detection capabilities by incorporating Oncimmune's autoantibody platform and expanding its multiomics portfolio. Oncimmune Ltd., a UK-based biotechnology firm, specializes in immunodiagnostics for cancer detection.

Major companies operating in the multi cancer early detection market are Illumina Inc., Sysmex Inostics GmbH, Exact Sciences Corporation, Natera Inc, Guardant Health, Core Diagnostics, Genecast Biotechnology Co. Ltd, Burning Rock Biotech Limited, Freenome Holdings Inc., Guangzhou AnchorDx Medical Co. Ltd, Singlera Genomics Incorporated, Naveris Inc. , Lucence Health Inc., PredOmix Technologies, Micronoma INC., EarlyDiagnostics (EarlyDx), Elypta AB, Predictive Oncology, ANPAC Bio-Medical Science Co. Ltd, CanSense Ltd, Epigenomics AG, VolitionRX, OncoSeek, Laboratory for Advanced Medicine, Inc., AnchorDx

North America was the largest region in the multi cancer early detection market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multi cancer early detection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the multi cancer early detection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The multi-cancer early detection market consists of revenues earned by entities by providing services such as diagnostic imaging, screening tests, molecular diagnostics, and risk assessment services. The market value includes the value of related goods sold by the service provider or included within the service offering. The multi-cancer early detection market also includes sales of assay panels, diagnostic kits, reagents, instruments, software solutions for data analysis and interpretation, and quality control materials. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Multi Cancer Early Detection Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on multi cancer early detection market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for multi cancer early detection ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The multi cancer early detection market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Liquid Biopsy; Gene Panel; Laboratory Developed Tests (LDT); Other Types
• 2) By Cancer Type: Solid Tumors; Hematological Malignancies
• 3) By End-User: Hospitals; Diagnostic Laboratories; Other End Users
• Subsegments:
• 1) By Liquid Biopsy Types: Circulating Tumor Cells (CTC); Circulating Tumor DNA (Ctdna); Exosomes
• 2) By Gene Panel: DNA-Based Panels; RNA-Based Panels; Multi-Gene Panels
• 3) By Laboratory Developed Tests (LDT): PCR-Based Tests; Next-Generation Sequencing (NGS) Tests; Immunohistochemistry (IHC) Tests
• 4) By Other Types: Protein Biomarkers; Autoantibody-Based Tests
• Companies Mentioned: Illumina Inc.; Sysmex Inostics GmbH; Exact Sciences Corporation; Natera Inc; Guardant Health
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Multi Cancer Early Detection Market Characteristics

3. Multi Cancer Early Detection Market Trends And Strategies

4. Multi Cancer Early Detection Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Multi Cancer Early Detection Growth Analysis And Strategic Analysis Framework

• 5.1. Global Multi Cancer Early Detection PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Multi Cancer Early Detection Market Growth Rate Analysis
• 5.4. Global Multi Cancer Early Detection Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Multi Cancer Early Detection Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Multi Cancer Early Detection Total Addressable Market (TAM)

6. Multi Cancer Early Detection Market Segmentation

• 6.1. Global Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Liquid Biopsy
• Gene Panel
• Laboratory Developed Tests (LDT)
• Other Types
• 6.2. Global Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Solid Tumors
• Hematological Malignancies
• 6.3. Global Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Diagnostic Laboratories
• Other End Users
• 6.4. Global Multi Cancer Early Detection Market, Sub-Segmentation Of Liquid Biopsy Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Circulating Tumor Cells (CTC)
• Circulating Tumor DNA (Ctdna)
• Exosomes
• 6.5. Global Multi Cancer Early Detection Market, Sub-Segmentation Of Gene Panel, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• DNA-Based Panels
• RNA-Based Panels
• Multi-Gene Panels
• 6.6. Global Multi Cancer Early Detection Market, Sub-Segmentation Of Laboratory Developed Tests (LDT), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• PCR-Based Tests
• Next-Generation Sequencing (NGS) Tests
• Immunohistochemistry (IHC) Tests
• 6.7. Global Multi Cancer Early Detection Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Protein Biomarkers
• Autoantibody-Based Tests

7. Multi Cancer Early Detection Market Regional And Country Analysis

• 7.1. Global Multi Cancer Early Detection Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Multi Cancer Early Detection Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Multi Cancer Early Detection Market

• 8.1. Asia-Pacific Multi Cancer Early Detection Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Multi Cancer Early Detection Market

• 9.1. China Multi Cancer Early Detection Market Overview
• 9.2. China Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Multi Cancer Early Detection Market

• 10.1. India Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Multi Cancer Early Detection Market

• 11.1. Japan Multi Cancer Early Detection Market Overview
• 11.2. Japan Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Multi Cancer Early Detection Market

• 12.1. Australia Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Multi Cancer Early Detection Market

• 13.1. Indonesia Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Multi Cancer Early Detection Market

• 14.1. South Korea Multi Cancer Early Detection Market Overview
• 14.2. South Korea Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Multi Cancer Early Detection Market

• 15.1. Western Europe Multi Cancer Early Detection Market Overview
• 15.2. Western Europe Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Multi Cancer Early Detection Market

• 16.1. UK Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Multi Cancer Early Detection Market

• 17.1. Germany Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Multi Cancer Early Detection Market

• 18.1. France Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Multi Cancer Early Detection Market

• 19.1. Italy Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Multi Cancer Early Detection Market

• 20.1. Spain Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Multi Cancer Early Detection Market

• 21.1. Eastern Europe Multi Cancer Early Detection Market Overview
• 21.2. Eastern Europe Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Multi Cancer Early Detection Market

• 22.1. Russia Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Multi Cancer Early Detection Market

• 23.1. North America Multi Cancer Early Detection Market Overview
• 23.2. North America Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Multi Cancer Early Detection Market

• 24.1. USA Multi Cancer Early Detection Market Overview
• 24.2. USA Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Multi Cancer Early Detection Market

• 25.1. Canada Multi Cancer Early Detection Market Overview
• 25.2. Canada Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Multi Cancer Early Detection Market

• 26.1. South America Multi Cancer Early Detection Market Overview
• 26.2. South America Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Multi Cancer Early Detection Market

• 27.1. Brazil Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Multi Cancer Early Detection Market

• 28.1. Middle East Multi Cancer Early Detection Market Overview
• 28.2. Middle East Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Multi Cancer Early Detection Market

• 29.1. Africa Multi Cancer Early Detection Market Overview
• 29.2. Africa Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Multi Cancer Early Detection Market Competitive Landscape And Company Profiles

• 30.1. Multi Cancer Early Detection Market Competitive Landscape
• 30.2. Multi Cancer Early Detection Market Company Profiles
  • 30.2.1. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sysmex Inostics GmbH Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Exact Sciences Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Natera Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Guardant Health Overview, Products and Services, Strategy and Financial Analysis

31. Multi Cancer Early Detection Market Other Major And Innovative Companies

• 31.1. Core Diagnostics
• 31.2. Genecast Biotechnology Co. Ltd
• 31.3. Burning Rock Biotech Limited
• 31.4. Freenome Holdings Inc.
• 31.5. Guangzhou AnchorDx Medical Co. Ltd
• 31.6. Singlera Genomics Incorporated
• 31.7. Naveris Inc.
• 31.8. Lucence Health Inc.
• 31.9. PredOmix Technologies
• 31.10. Micronoma INC.
• 31.11. EarlyDiagnostics (EarlyDx)
• 31.12. Elypta AB
• 31.13. Predictive Oncology
• 31.14. ANPAC Bio-Medical Science Co. Ltd
• 31.15. CanSense Ltd

32. Global Multi Cancer Early Detection Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Multi Cancer Early Detection Market

34. Recent Developments In The Multi Cancer Early Detection Market

35. Multi Cancer Early Detection Market High Potential Countries, Segments and Strategies

• 35.1 Multi Cancer Early Detection Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Multi Cancer Early Detection Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Multi Cancer Early Detection Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer